A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19
The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health concern. Three years since its origin, despite the approval of vaccines and specific treatments against this new coronavirus, there are still high rate...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-04-01
|
| Series: | International Journal of Molecular Sciences |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1422-0067/24/9/7865 |
| _version_ | 1797602491143028736 |
|---|---|
| author | Vitoria Guero Korb Iago Carvalho Schultz Liziane Raquel Beckenkamp Márcia Rosângela Wink |
| author_facet | Vitoria Guero Korb Iago Carvalho Schultz Liziane Raquel Beckenkamp Márcia Rosângela Wink |
| author_sort | Vitoria Guero Korb |
| collection | DOAJ |
| description | The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health concern. Three years since its origin, despite the approval of vaccines and specific treatments against this new coronavirus, there are still high rates of infection, hospitalization, and mortality in some countries. COVID-19 is characterised by a high inflammatory state and coagulation disturbances that may be linked to purinergic signalling molecules such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine (ADO), and purinergic receptors (P1 and P2). These nucleotides/nucleosides play important roles in cellular processes, such as immunomodulation, blood clot formation, and vasodilation, which are affected during SARS-CoV-2 infection. Therefore, drugs targeting this purinergic pathway, currently used for other pathologies, are being evaluated in preclinical and clinical trials for COVID-19. In this review, we focus on the potential of these drugs to control the release, degradation, and reuptake of these extracellular nucleotides and nucleosides to treat COVID-19. Drugs targeting the P1 receptors could have therapeutic efficacy due to their capacity to modulate the cytokine storm and the immune response. Those acting in P2X7, which is linked to NLRP3 inflammasome activation, are also valuable candidates as they can reduce the release of pro-inflammatory cytokines. However, according to the available preclinical and clinical data, the most promising medications to be used for COVID-19 treatment are those that modulate platelets behaviour and blood coagulation factors, mainly through the P2Y12 receptor. |
| first_indexed | 2024-03-11T04:16:47Z |
| format | Article |
| id | doaj.art-05873b6c7f9648f09f9872328093b0a0 |
| institution | Directory Open Access Journal |
| issn | 1661-6596 1422-0067 |
| language | English |
| last_indexed | 2024-03-11T04:16:47Z |
| publishDate | 2023-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | International Journal of Molecular Sciences |
| spelling | doaj.art-05873b6c7f9648f09f9872328093b0a02023-11-17T23:01:39ZengMDPI AGInternational Journal of Molecular Sciences1661-65961422-00672023-04-01249786510.3390/ijms24097865A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19Vitoria Guero Korb0Iago Carvalho Schultz1Liziane Raquel Beckenkamp2Márcia Rosângela Wink3Laboratório de Biologia Celular, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, RS, BrazilLaboratório de Biologia Celular, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, RS, BrazilLaboratório de Biologia Celular, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, RS, BrazilLaboratório de Biologia Celular, Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSPA), Porto Alegre 90050-170, RS, BrazilThe coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global health concern. Three years since its origin, despite the approval of vaccines and specific treatments against this new coronavirus, there are still high rates of infection, hospitalization, and mortality in some countries. COVID-19 is characterised by a high inflammatory state and coagulation disturbances that may be linked to purinergic signalling molecules such as adenosine triphosphate (ATP), adenosine diphosphate (ADP), adenosine (ADO), and purinergic receptors (P1 and P2). These nucleotides/nucleosides play important roles in cellular processes, such as immunomodulation, blood clot formation, and vasodilation, which are affected during SARS-CoV-2 infection. Therefore, drugs targeting this purinergic pathway, currently used for other pathologies, are being evaluated in preclinical and clinical trials for COVID-19. In this review, we focus on the potential of these drugs to control the release, degradation, and reuptake of these extracellular nucleotides and nucleosides to treat COVID-19. Drugs targeting the P1 receptors could have therapeutic efficacy due to their capacity to modulate the cytokine storm and the immune response. Those acting in P2X7, which is linked to NLRP3 inflammasome activation, are also valuable candidates as they can reduce the release of pro-inflammatory cytokines. However, according to the available preclinical and clinical data, the most promising medications to be used for COVID-19 treatment are those that modulate platelets behaviour and blood coagulation factors, mainly through the P2Y12 receptor.https://www.mdpi.com/1422-0067/24/9/7865COVID-19SARS-CoV-2purinergic signallingpurinergic receptors |
| spellingShingle | Vitoria Guero Korb Iago Carvalho Schultz Liziane Raquel Beckenkamp Márcia Rosângela Wink A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19 International Journal of Molecular Sciences COVID-19 SARS-CoV-2 purinergic signalling purinergic receptors |
| title | A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19 |
| title_full | A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19 |
| title_fullStr | A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19 |
| title_full_unstemmed | A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19 |
| title_short | A Systematic Review of the Role of Purinergic Signalling Pathway in the Treatment of COVID-19 |
| title_sort | systematic review of the role of purinergic signalling pathway in the treatment of covid 19 |
| topic | COVID-19 SARS-CoV-2 purinergic signalling purinergic receptors |
| url | https://www.mdpi.com/1422-0067/24/9/7865 |
| work_keys_str_mv | AT vitoriaguerokorb asystematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT iagocarvalhoschultz asystematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT lizianeraquelbeckenkamp asystematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT marciarosangelawink asystematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT vitoriaguerokorb systematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT iagocarvalhoschultz systematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT lizianeraquelbeckenkamp systematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 AT marciarosangelawink systematicreviewoftheroleofpurinergicsignallingpathwayinthetreatmentofcovid19 |